EGFR及Mfn2在乳腺癌进展中的意义及其相关性研究

Significance and the relevance study of EGFR and Mfn2 in the progression of breast cancer

目的研究外周血线粒体融合蛋白2(Mfn2)在表皮生长因子受体(EGFR)为阳性的乳腺癌患者疾病进展中的表达情况,探讨其与EGFR及乳腺癌预后的关系。方法选择EGFR阳性乳腺癌患者44例,检测其外周血Mfn2 mRNA表达。随访3年出现疾病进展时,再次检测患者外周血Mfn2 mRNA表达情况。结果 26例患者出现疾病进展,外周血Mfn2阳性表达组疾病进展率为42.1%(8/19),阴性组疾病进展率为72.0%(18/25),差异具有统计学意义(P<0.05);疾病进展后,阳性组Mfn2阳性率降至52.63%(10/19),阴性组阳性表达率为0%;阳性组出现疾病进展患者阳性率为25.00%(2/8),未进展患者阳性率72.72%(8/11),差异具有统计学意义(P<0.05)。结论 EGFR、Mfn2在乳腺癌的复发、转移中发挥重要作用,联合检测EGFR、Mfn2可能作为监测乳腺癌进展、提高乳腺癌复发的诊断效率及预测肿瘤预后的重要生物学指标。

Objective To study the expression of peripheral blood Mitochondria fusion protein-2（Mfn2） in the disease progression of breast cancer patients with positive epidermal growth factor receptor（EGFR） and to explore its relationship with EGFR and the prognosis of patients with breast cancer. Methods EGFR expression in the cancerous tissue of patients with breast cancer was detected by histoimmunochemical method,in which 44 patients with positive expression of EGFR were selected. The expression of peripheral blood mfn2 mRNA was detected,which was re-detected when disease progressed after 3 years-follow-up. Results Of all patients,26 patients had disease progression. The disease progression rates in positive and negative expression groups of peripheral blood Mfn2 were 42. 1%（8 /19） and 72. 0%（18 /25）,respectively,and the difference was significant（P〈 0. 05）. After disease progression,the positive expression rates of Mfn2 in positive and negative expression groups decreased to 52. 63%（10 /19） and 0%. And the positive rates of patients with disease progression in positive expression group and non-disease progression group were 25. 00%（2 /8）and 72. 72%（8 /11）,respectively,and the differences were significant（P〈 0. 05）. Conclusion EGFR and Mfn2 play an important role in the recurrence and metastasis of breast cancer,and their joint detection can be used as an critical biological marker for the surveillance of disease progression and promote the diagnostic rate of the recurrence and the prognosis of breast cancer.